AEHR stock forecast has been upgraded following stronger-than-expected backlog growth reports. This strategic positioning in next-gen semiconductor testing markets has amplified long-term bullish scenarios. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. AEHR trying to recover from the bottom. Hitting key Resistance repeatedly at $8.79-8.89 If sdip then watch the Golden Covid fib at $7.90 Analysts revising AEHR stock forecast point to strong balance sheet liquidity and zero long-term debt, improving investor confidence. Price targets have shifted from $29 to $34 for Q2 as institutional buying increases.